Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

The Spotlight Study: Early Identification of Post-Surgical Infections Using Bedside Ultrasound.

NCT07549880 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2026-04-10
Last updated
2026-04-24

Condition(s) studied

Surgical Site Infection (SSI)Emergency LaparotomiesPoint of Care Ultrasound (POCUS)

Investigational drug(s) / intervention(s)

Point-of-Care Ultrasound (POCUS)Microbiological Wound SwabASEPSIS Wound AssessmentStandardized Wound Photography

Point-of-Care Ultrasound (POCUS): Three standardized postoperative ultrasound examinations performed on post-operative day 1-3, 4-6, and 7-9 to measure subcutaneous fluid collections and assess the risk of surgical site infection.

Microbiological Wound Swab: Single postoperative swab of the closed incision and surrounding skin obtained between POD 1-3 for microbiological assessment.

ASEPSIS Wound Assessment: Structured wound scoring performed at each postoperative assessment to evaluate clinical signs of surgical site infection.

Standardized Wound Photography: Photographic documentation of the surgical incision at each postoperative assessment to support blinded evaluation.

Study summary

Introduction:

The goal of this observational study is to learn whether point-of-care ultrasound (POCUS) can help detect early fluid build-up under the skin after open abdominal surgery (laparotomy) and whether these findings can predict surgical site infection. The study includes adults who recently had emergency or planned open abdominal surgery.

Hypothesis:

The main questions it aims to answer are:

1. Does ultrasound identify subcutaneous fluid collections early after surgery?
2. Do these fluid collections help predict which participants will develop a surgical site infection?

Intervention:

Participants will:

1. Have a superficial wound swab taken once at the start of the study (for research only).
2. Receive three ultrasound scans of their surgical wound during days 1-3, 4-6, and 7-9 after surgery.
3. Have their wound checked for redness, swelling, tenderness, or discharge before each scan.
4. Be followed for 7 and 30 days after surgery (and up to 90 days if they have implanted mesh) to see whether an infection develops.

Ultrasound is non-invasive and safe. According to the protocol, "no serious adverse effects are expected," though some participants may feel brief discomfort from pressure on a tender wound.

This study will help researchers understand whether routine bedside ultrasound can support earlier detection of wound infections and improve postoperative care in the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults \>18 years. * Undergoing emergency or elective laparotomy. * Primary or delayed primary wound closure (DPC). * Wound classification: clean, clean-contaminated, contaminated, or dirty. * Informed consent obtained. Exclusion Criteria: * Laparoscopic surgery * Wounds healing by secondary intention. * Ongoing wound dehiscence treatment with Negative Pressure Wound Therapy (NPWT). * Non-Danish residents

Primary outcome measure(s)

  • Incidence of surgical site infection (SSI) within 30 days stratified by presence of POCUS-detected subcutaneous fluid — 30 days post-operative
    SSI occurrence will be compared between participants with and without postoperative subcutaneous fluid collections detected on point-of-care ultrasound. SSI will be defined according to CDC criteria. Fluid presence and volume will be recorded during scheduled POCUS examinations.

Trial sites (3)

FacilityCityRegionStatus
Copenhagen University Hospital - Herlev & Gentofte Herlev Capital Region Recruiting
Zealand University Hospital - Køge Køge Region Sjælland Recruiting
Slagelse Hospital Slagelse Region Sjælland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07549880 on ClinicalTrials.gov ↗ ← All trials in Denmark